Published in Hum Mol Genet on April 29, 2009
Paternal age effect mutations and selfish spermatogonial selection: causes and consequences for human disease. Am J Hum Genet (2012) 1.78
Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. Nat Genet (2009) 1.72
Proliferation rate of somatic cells affects reprogramming efficiency. J Biol Chem (2013) 0.92
Differential regulation of N-Myc and c-Myc synthesis, degradation, and transcriptional activity by the Ras/mitogen-activated protein kinase pathway. J Biol Chem (2011) 0.80
Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma. Proc Natl Acad Sci U S A (2016) 0.78
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell (1997) 29.13
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
An oncogene-induced DNA damage model for cancer development. Science (2008) 11.60
Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature (2006) 11.18
The p53 pathway: positive and negative feedback loops. Oncogene (2005) 9.75
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev (1998) 9.03
Intrinsic tumour suppression. Nature (2004) 8.73
A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell (2006) 6.96
c-MYC: more than just a matter of life and death. Nat Rev Cancer (2002) 6.73
Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev (1998) 5.60
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet (1999) 5.29
Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev (1998) 5.14
The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev (2007) 4.91
c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature (2001) 4.46
Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J (1998) 4.14
DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene (2007) 3.67
Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol (2008) 3.49
Myc pathways provoking cell suicide and cancer. Oncogene (2003) 3.49
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A (2007) 3.37
Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A (2008) 3.30
Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev (2005) 3.28
Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet (1997) 3.11
Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene (2007) 2.83
Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res (2001) 2.77
Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol (2006) 2.58
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood (2001) 2.48
FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res (2008) 2.46
Many roads lead to oncogene-induced senescence. Oncogene (2008) 2.43
Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci U S A (2005) 2.38
A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood (1997) 2.31
RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis. Nat Genet (2007) 2.22
Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. Proc Natl Acad Sci U S A (2000) 2.13
Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev (2005) 2.10
Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum Mol Genet (2004) 1.92
Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res (2008) 1.87
Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. Hum Mol Genet (1998) 1.83
Fibroblast growth factor receptor 3 mutations in epidermal nevi and associated low grade bladder tumors. J Invest Dermatol (2007) 1.78
Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res (2004) 1.78
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet (2005) 1.74
C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Oncogene (2008) 1.70
Cancer genomics and genetics of FGFR2 (Review). Int J Oncol (2008) 1.55
Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis (2005) 1.54
Activation of FGF receptors by mutations in the transmembrane domain. Oncogene (1997) 1.38
High frequency of FGFR3 mutations in adenoid seborrheic keratoses. J Invest Dermatol (2006) 1.37
Mnt-Max to Myc-Max complex switching regulates cell cycle entry. J Cell Biol (2005) 1.25
Deletion of Mnt leads to disrupted cell cycle control and tumorigenesis. EMBO J (2003) 1.17
The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood (2001) 1.17
A dominant repression domain in Tbx3 mediates transcriptional repression and cell immortalization: relevance to mutations in Tbx3 that cause ulnar-mammary syndrome. Hum Mol Genet (2001) 1.13
A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation. Cancer Res (2001) 1.10
Roles of FGF signaling in skeletal development and human genetic diseases. Front Biosci (2005) 1.03
Development and validation of a clinical risk score predicting the no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Cardiology (2013) 1.47
Of Myc and Mnt. J Cell Sci (2006) 1.31
Mnt-Max to Myc-Max complex switching regulates cell cycle entry. J Cell Biol (2005) 1.25
Deletion of Mnt leads to disrupted cell cycle control and tumorigenesis. EMBO J (2003) 1.17
Tbx3 impinges on the p53 pathway to suppress apoptosis, facilitate cell transformation and block myogenic differentiation. Oncogene (2002) 1.12
Loss of the Max-interacting protein Mnt in mice results in decreased viability, defective embryonic growth and craniofacial defects: relevance to Miller-Dieker syndrome. Hum Mol Genet (2004) 1.00
Activities of N-Myc in the developing limb link control of skeletal size with digit separation. Development (2007) 0.99
Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice. Eur J Immunol (2004) 0.99
A critical role for Mnt in Myc-driven T-cell proliferation and oncogenesis. Proc Natl Acad Sci U S A (2012) 0.93
Rationally designed mutations convert complexes of human recombinant T cell receptor ligands into monomers that retain biological activity. J Chem Technol Biotechnol (2005) 0.92
Mnt transcriptional repressor is functionally regulated during cell cycle progression. Oncogene (2005) 0.92
Development of human gene reporter cell lines using rAAV mediated homologous recombination. Biol Proced Online (2007) 0.89
Inflammatory disease and lymphomagenesis caused by deletion of the Myc antagonist Mnt in T cells. Mol Cell Biol (2006) 0.88
OX40 engagement stabilizes Mxd4 and Mnt protein levels in antigen-stimulated T cells leading to an increase in cell survival. Eur J Immunol (2011) 0.85
AlphaB-crystallin-reactive T cells from knockout mice are not encephalitogenic. J Neuroimmunol (2006) 0.85
Sequential and coordinated actions of c-Myc and N-Myc control appendicular skeletal development. PLoS One (2011) 0.83
Disruption of a Sox9-β-catenin circuit by mutant Fgfr3 in thanatophoric dysplasia type II. Hum Mol Genet (2012) 0.82
Differential regulation of N-Myc and c-Myc synthesis, degradation, and transcriptional activity by the Ras/mitogen-activated protein kinase pathway. J Biol Chem (2011) 0.80
Prevalence of arterial stiffness in North China, and associations with risk factors of cardiovascular disease: a community-based study. BMC Cardiovasc Disord (2012) 0.78
MYC needs MNT. Cell Cycle (2013) 0.76
A repressor protein, Mnt, is a novel negative regulator of vascular smooth muscle cell hypertrophy by angiotensin II and neointimal hyperplasia by arterial injury. Atherosclerosis (2013) 0.76
A risk score for no reflow in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention. Clin Cardiol (2015) 0.75
Evidence of mnt-myc antagonism revealed by mnt gene deletion. Cell Cycle (2004) 0.75